Cancer Family
Soft Tissue Neoplasm
CI-CAN-00000354Explore in graph →
Non-malignant441 active trials9 approved drugs183 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000354Explore in graph →
Clinical trials
2,078 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02654054 | Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women | completed | Phase 3 | 413 | AbbVieINDUSTRY | 3 | Jun 29, 2020 | clinicaltrials |
| NCT01533207 | Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery | terminated | Phase 3 | 38 | Gynecologic Oncology GroupNETWORK | 8 |
| Apr 28, 2020 |
| clinicaltrials |
| NCT03520959 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) | terminated | Phase 3 | 1 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Apr 16, 2020 | clinicaltrials |
| NCT03699176 | Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 7) | withdrawn | Phase 3 | 0 | BayerINDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01151852 | Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT | completed | Phase 3 | 81 | Asan Medical CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT01352117 | Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma(REACT-KS) | completed | Phase 3 | 192 | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNETWORK | 6 | Nov 14, 2019 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
| NCT01629563 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLIV) | completed | Phase 3 | 451 | PregLem SAINDUSTRY | 11 | Sep 4, 2019 | clinicaltrials |
| NCT02147158 | A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas | completed | Phase 3 | 432 | AllerganINDUSTRY | 2 | Jun 4, 2019 | clinicaltrials |
| NCT03773510 | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin(TRADITIONS) | withdrawn | Phase 3 | 0 | Italian Sarcoma GroupNETWORK | 1 | May 13, 2019 | clinicaltrials |
| NCT02147197 | A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas | completed | Phase 3 | 157 | AllerganINDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
| NCT02655224 | A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids | completed | Phase 3 | 65 | TakedaINDUSTRY | 1 | Mar 22, 2019 | clinicaltrials |
| NCT02655237 | A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids | completed | Phase 3 | 281 | TakedaINDUSTRY | 1 | Mar 22, 2019 | clinicaltrials |
| NCT03874273 | Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors | unknown | Phase 2 / Phase 3 | 25 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Mar 14, 2019 | clinicaltrials |
| NCT02634931 | Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex | completed | Phase 3 | 94 | NobelpharmaINDUSTRY | 1 | Feb 20, 2019 | clinicaltrials |
| NCT00365989 | MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication | completed | Phase 3 | 50 | InSightecINDUSTRY | 2 | Feb 5, 2019 | clinicaltrials |
| NCT00295217 | MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation | completed | Phase 3 | 15 | InSightecINDUSTRY | 1 | Dec 20, 2018 | clinicaltrials |
| NCT02942537 | Study of Volume Reduction of Uterine Fibroids After Embolization or Microwave Treatment(MYOMIC1) | unknown | Phase 2 / Phase 3 | 36 | Karolinska InstitutetOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT00103168 | Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor | completed | Phase 3 | 908 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 9, 2018 | clinicaltrials |
| NCT03509168 | The Efficacy and Safety of Preoperative Misoprostol in Blood-loss Reduction During Myomectomy.(MM) | unknown | Phase 2 / Phase 3 | 46 | Makerere UniversityOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT02736435 | Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound | withdrawn | Phase 3 | 0 | Thunder Bay Regional Health Research InstituteOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT00528606 | AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture(CORD-I) | completed | Phase 3 | 308 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01265810 | Caphosol in Oral Mucositis Due to Targeted Therapy(COMTT) | completed | Phase 3 | 64 | Impaqtt FoundationOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01715597 | Study on the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women With Uterine Myoma | completed | Phase 3 | 50 | Seoul National University HospitalOTHER | 1 | Oct 31, 2017 | clinicaltrials |
| NCT01407068 | Administration of Two Injections for Multiple Dupuytren's Contractures | completed | Phase 3 | 60 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 2 | Oct 5, 2017 | clinicaltrials |
| NCT01674634 | Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures | completed | Phase 3 | 715 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Oct 5, 2017 | clinicaltrials |
| NCT00324987 | Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor(S0502) | terminated | Phase 3 | 12 | National Cancer Institute (NCI)NIH | 2 | Sep 14, 2017 | clinicaltrials |
| NCT03122782 | Hemostatic Effect of Intrauterine Instillation Of Tranexamic Acid In Hysteroscopic Myomectomy | unknown | Phase 3 | 80 | Ain Shams UniversityOTHER | 0 | Jun 29, 2017 | clinicaltrials |
| NCT02449343 | Study of Anlotinib in Patients With Soft Tissue Sarcoma(STS)(ALTER0203) | unknown | Phase 2 / Phase 3 | 233 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01504308 | Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids(SOFIA) | terminated | Phase 2 / Phase 3 | 49 | Philips HealthcareINDUSTRY | 3 | Apr 5, 2017 | clinicaltrials |
| NCT01588353 | Collagenase Option for Reduction of Dupuytren's Contracture in Japan(CORD-J) | completed | Phase 3 | 104 | Asahi Kasei Therapeutics CorporationINDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT00790400 | Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)(EXIST-2) | completed | Phase 3 | 118 | Novartis PharmaceuticalsINDUSTRY | 11 | Feb 17, 2017 | clinicaltrials |
| NCT02635789 | Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) | completed | Phase 3 | 62 | NobelpharmaINDUSTRY | 1 | Feb 2, 2017 | clinicaltrials |
| NCT01289028 | Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. | completed | Phase 3 | 125 | Novartis PharmaceuticalsINDUSTRY | 2 | Jan 2, 2017 | clinicaltrials |
| NCT02866045 | EUS-FNB vs. Single-incision Needle-knife (SINK) Biopsy for Gastrointestinal SELs | unknown | Phase 3 | 104 | Unity Health TorontoOTHER | 1 | Aug 15, 2016 | clinicaltrials |
| NCT00785785 | A Study of Nilotinib Versus Imatinib in GIST Patients(ENESTg1) | completed | Phase 3 | 644 | Novartis PharmaceuticalsINDUSTRY | 35 | Jun 16, 2016 | clinicaltrials |
| NCT01440088 | A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma | completed | Phase 3 | 640 | Threshold PharmaceuticalsINDUSTRY | 13 | Jun 2, 2016 | clinicaltrials |
| NCT01462994 | Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST) | completed | Phase 3 | 25 | Technical University of MunichOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01156857 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLIII) | completed | Phase 3 | 209 | PregLem SAINDUSTRY | 4 | Jan 15, 2016 | clinicaltrials |
| NCT01252069 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study) | completed | Phase 3 | 132 | PregLem SAINDUSTRY | 4 | Jan 13, 2016 | clinicaltrials |
| NCT01642472 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLext2) | completed | Phase 3 | 64 | PregLem SAINDUSTRY | 4 | Jan 8, 2016 | clinicaltrials |
| NCT02576080 | Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index(GIGIST) | unknown | Phase 3 | 80 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Oct 15, 2015 | clinicaltrials |
| NCT00293124 | Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors | completed | Phase 3 | 125 | Central European Cooperative Oncology GroupOTHER | 10 | Aug 13, 2015 | clinicaltrials |
| NCT00002706 | Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus | completed | Phase 3 | 2,616 | Gynecologic Oncology GroupNETWORK | 1 | May 29, 2015 | clinicaltrials |
| NCT00014742 | Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease | completed | Phase 3 | 72 | State University of New YorkOTHER | 0 | Mar 25, 2015 | clinicaltrials |
| NCT00538239 | Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)(SUCCEED) | completed | Phase 3 | 711 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 13, 2015 | clinicaltrials |
| NCT00009906 | Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor | terminated | Phase 3 | 748 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT00834457 | A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe | completed | Phase 2 / Phase 3 | 49 | Parirenyatwa HospitalOTHER | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00886873 | Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids(Mifemyo_2) | completed | Phase 2 / Phase 3 | 100 | Mediterranea Medica S. L.OTHER | 1 | Oct 17, 2014 | clinicaltrials |
| NCT01786226 | Mifepristone to Treat Uterine Fibroids | terminated | Phase 2 / Phase 3 | 220 | Mediterranea Medica S. L.OTHER | 1 | Sep 5, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Jun 29, 2020source: clinicaltrials